

## CME/CE/CPE POSTTEST

Please circle your answer and submit with your CME/CE/CPE Registration Form/Evaluation

1. **The annual incidence of HCV infection in the United States is declining.**
  - a. True
  - b. False
2. **Which of the following ethnic groups in the United States has the highest prevalence of HCV infection?**
  - a. Caucasian
  - b. Hispanic
  - c. African American
  - d. Asian
  - e. Unknown
3. **Intravenous drug use currently accounts for 50% of the newly acquired HCV infections in the United States.**
  - a. True
  - b. False
4. **Approximately 10% of HCV patients failing to achieve an EVR (12-weeks) with peginterferon and ribavirin will go on to achieve an SVR.**
  - a. True
  - b. False
5. **Over a 20–40 year period, approximately 10%–20% of chronically infected HCV patients will develop liver cirrhosis.**
  - a. True
  - b. False
6. **Which of the following factors does not impact the progression of fibrosis in HCV infected individuals?**
  - a. HCV viral burden
  - b. HCV genotype
  - c. HCV/HIV co-infection
  - d. Alcohol consumption
  - e. All of the above factors impact the progression of fibrosis
7. **Patients diagnosed with chronic HCV at a young age are more likely to develop cirrhosis than patients diagnosed at an older age.**
  - a. True
  - b. False



8. Interferons are classified according to the type of cell surface receptor they bind to.
  - a. True
  - b. False
9. HCV quasispecies are genetically distant yet closely related variants with 91%–99% sequence homology.
  - a. True
  - b. False
10. The first phase of viral decline during interferon therapy occurs over approximately 10 days.
  - a. True
  - b. False
11. Interferon-stimulated gene products are the effectors of antiviral actions associated with the administration of interferon therapies.
  - a. True
  - b. False
12. Pegylation of an interferon decreases its antiviral activity in vitro.
  - a. True
  - b. False
13. Which of the following is the primary goal of retreatment HCV patients who failed to respond to their initial course of interferon-based therapy?
  - a. Improve hepatic histology
  - b. Reduce the risk of developing HCC
  - c. Eradicate HCV infection
  - d. Slow overall disease progression
  - e. None of the above
14. An SVR following interferon treatment is necessary for HCV patients to realize any histologic benefit.
  - a. True
  - b. False
15. Maintenance interferon therapy has been definitively shown to reduce the long-term risk of developing liver cirrhosis.
  - a. True
  - b. False

## CME/CE/CPE REGISTRATION FORM/EVALUATION

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP Code: \_\_\_\_\_

E-mail Address: \_\_\_\_\_

Please indicate your degree(s):     MD     DO     PharmD     NP     Other (please specify) \_\_\_\_\_

PHYSICIANS: Are you licensed in the US?     Yes     No

I certify that I completed this CME/CE/CPE activity. The actual amount of time I spent in this activity was: \_\_\_\_\_Hours \_\_\_\_\_Minutes

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

The France Foundation would appreciate your comments regarding the quality of this activity. In the future, we would like to send you a follow-up survey regarding the material presented to measure the educational outcomes of this activity. May we contact you?

- Yes, via e-mail.    Address: \_\_\_\_\_@\_\_\_\_\_
- Yes, via fax.    Fax Number: (\_\_\_\_\_) \_\_\_\_\_
- Yes, via US mail.
- No, please do not contact me.

Please circle the number that best reflects your response.

**4 - Strongly Agree    3 - Agree    2 - Disagree    1 - Strongly Disagree**

The Resource Center enhanced my understanding of HCV treatment failures	4	3	2	1
Material was well organized	4	3	2	1
Content had relevance to my practice	4	3	2	1
Patient Education Tools will be useful	4	3	2	1

Comments: \_\_\_\_\_

**4 - Outstanding    3 - Good    2 - Fair    1 - Poor**

1. To what degree did the Resource Center meet your objectives?	4	3	2	1
2. To what degree did the Resource Center meet the following stated objectives?				
• Explain the hepatitis C virus infection and the consequences of treatment failure	4	3	2	1
• Describe the underlying scientific basis for HCV treatment failure	4	3	2	1
3. To what degree did the Resource Center provide you the information to:				
• Utilize knowledge learned concerning therapeutic options for patients who fail initial HCV treatment to improve your management of treatment failures?	4	3	2	1
• Apply knowledge gained from reviewing the interactive cases to enhance outcomes for HCV infected patients experiencing treatment failure?	4	3	2	1
4. How will this Resource Center affect your professional practice objectives?				



*Will modify the manner of scope and practice.*

- Not at all                       Moderately                       Considerably

Example: \_\_\_\_\_

*Will improve your diagnostic skills.*

- Not at all                       Moderately                       Considerably

Example: \_\_\_\_\_

*Will improve or change your patient management approaches.*

- Not at all                       Moderately                       Considerably

Example: \_\_\_\_\_

**5. The information was without promotional or commercial bias.**

(When answering this question, please refer to the following guidelines set forth by the ACCME regarding commercial bias and fair balance: *Discussion of commercial products must be free of bias for or against any one product and must present objective information about each product discussed; only generic names of therapeutic options should be used, however if trade names are used, those of several companies must be discussed in the activity.*)

- Strongly Agree                       Agree                       Disagree                       Strongly Disagree

**6. Comments/suggestions regarding this CME/CE/CPE activity.**

---

---

**7. Recommendations for future educational activities.**

---

---

**If CME/CE/CPE credit and certificate are desired, please mail/fax this completed form and the CME/CE/CPE Posttest to:**

The France Foundation  
Attn: PHOENIX Secretariat  
230 Shore Road, Suite 202  
Old Lyme, Connecticut 06371  
Toll free: 1-866-227-6411  
Fax: 1-866-227-6412